Combined or High Dose Immunosuppression in Inflammatory Bowel Disease patients who are NUDT15 Homozygous Harbors Risk of Developing Invasive Fungal Infections: A Case Series

David Mathew Thomas; Sandeep Kumar Mundhra; Shubham Prasad; Shekhar Swaroop; Umang Arora; Syed Ahmed; Ashu Seith Bhalla; Raju Sharma; Prasenjit Das; Saurabh Kedia; Vineet Ahuja

doi:10.1093/ibd/izae104

Combined or High Dose Immunosuppression in Inflammatory Bowel Disease patients who are NUDT15 Homozygous Harbors Risk of Developing Invasive Fungal Infections: A Case Series

Inflamm Bowel Dis. 2024 Sep 3;30(9):1623-1625. doi: 10.1093/ibd/izae104.

Affiliations

¹ Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi 110029, India.
² Department of Radiodiagnosis, All India Institute of Medical Sciences, New Delhi 110029, India.
³ Department of Pathology, All India Institute of Medical Sciences, New Delhi 110029, India.

PMID: 38757903
DOI: 10.1093/ibd/izae104

No abstract available

Plain language summary

NUDT15 homozygous mutations predispose patients to severe leucopenia, which invites risk of disseminated fungal infections when high doses or a combination of immunosuppressives are administered in this patient population.

Publication types

Letter
Case Reports

MeSH terms

Adult
Female
Homozygote
Humans
Immunosuppressive Agents* / adverse effects
Inflammatory Bowel Diseases* / drug therapy
Inflammatory Bowel Diseases* / genetics
Invasive Fungal Infections / genetics
Male
Middle Aged
Nudix Hydrolases
Pyrophosphatases* / genetics

Substances

NUDT15 protein, human
Immunosuppressive Agents
Pyrophosphatases
Nudix Hydrolases